Tom Newsom-Davis
@tnewsomdavis.bsky.social
Thoracic medical oncologist | Chelsea & Westminster Hospital, London, UK | Chair British Thoracic Oncology Group
Reposted by Tom Newsom-Davis
There is healthy skepticism and there is this...
May 10, 2025 at 10:27 PM
There is healthy skepticism and there is this...
Going through applications for BTOG Trainee Representatives in oncology and respiratory medicine
The most extraordinary group of dynamic, motivated, committed individuals
So impressive
So hard to decide
Every single one would be excellent
The most extraordinary group of dynamic, motivated, committed individuals
So impressive
So hard to decide
Every single one would be excellent
a man with a beard is standing in front of a microphone scratching his head
ALT: a man with a beard is standing in front of a microphone scratching his head
media.tenor.com
May 9, 2025 at 9:28 PM
Going through applications for BTOG Trainee Representatives in oncology and respiratory medicine
The most extraordinary group of dynamic, motivated, committed individuals
So impressive
So hard to decide
Every single one would be excellent
The most extraordinary group of dynamic, motivated, committed individuals
So impressive
So hard to decide
Every single one would be excellent
Reposted by Tom Newsom-Davis
On our next livestreams: a look at how #LungCancer affects young people and women, with moderator Dr. Isabel Preeshagul.
Wed, April 23: Young Lung Cancer w/ Dr. Eric Singhi @lungoncdoc.bsky.social, LCRF.org/together2
Wed, May 14: Women & Lung Cancer w/ Dr. Narjust Florez, LCRF.org/together
Wed, April 23: Young Lung Cancer w/ Dr. Eric Singhi @lungoncdoc.bsky.social, LCRF.org/together2
Wed, May 14: Women & Lung Cancer w/ Dr. Narjust Florez, LCRF.org/together
April 16, 2025 at 4:04 PM
On our next livestreams: a look at how #LungCancer affects young people and women, with moderator Dr. Isabel Preeshagul.
Wed, April 23: Young Lung Cancer w/ Dr. Eric Singhi @lungoncdoc.bsky.social, LCRF.org/together2
Wed, May 14: Women & Lung Cancer w/ Dr. Narjust Florez, LCRF.org/together
Wed, April 23: Young Lung Cancer w/ Dr. Eric Singhi @lungoncdoc.bsky.social, LCRF.org/together2
Wed, May 14: Women & Lung Cancer w/ Dr. Narjust Florez, LCRF.org/together
Reposted by Tom Newsom-Davis
Exciting news!
@curetoday.bsky.social is hosting an incredible Young-Onset Lung Cancer Summit 🎉 Chaired by the amazing
@lungoncdoc.bsky.social, this is a must-attend event for anyone looking to learn more about @younglungcancer.bsky.social!
@curetoday.bsky.social is hosting an incredible Young-Onset Lung Cancer Summit 🎉 Chaired by the amazing
@lungoncdoc.bsky.social, this is a must-attend event for anyone looking to learn more about @younglungcancer.bsky.social!
April 3, 2025 at 1:52 PM
Exciting news!
@curetoday.bsky.social is hosting an incredible Young-Onset Lung Cancer Summit 🎉 Chaired by the amazing
@lungoncdoc.bsky.social, this is a must-attend event for anyone looking to learn more about @younglungcancer.bsky.social!
@curetoday.bsky.social is hosting an incredible Young-Onset Lung Cancer Summit 🎉 Chaired by the amazing
@lungoncdoc.bsky.social, this is a must-attend event for anyone looking to learn more about @younglungcancer.bsky.social!
Reposted by Tom Newsom-Davis
Happy to share our latest work, led by Dr Monaca. In a time-dependent analysis, we show that irAEs are associated with improved outcomes in ES-SCLC. Interestingly, neither high-grade irAEs nor the use of steroids appeared to negatively impact survival. www.sciencedirect.com/science/arti...
April 22, 2025 at 6:01 PM
Happy to share our latest work, led by Dr Monaca. In a time-dependent analysis, we show that irAEs are associated with improved outcomes in ES-SCLC. Interestingly, neither high-grade irAEs nor the use of steroids appeared to negatively impact survival. www.sciencedirect.com/science/arti...
Not only does ‘Repositories of Agriculture’ debase scientific publications through unsolicited paper requests, but they then get aggressive when you don’t reply.
Extraordinary
Think they need to review their PR skills (and conscience)
Extraordinary
Think they need to review their PR skills (and conscience)
April 22, 2025 at 12:00 PM
Not only does ‘Repositories of Agriculture’ debase scientific publications through unsolicited paper requests, but they then get aggressive when you don’t reply.
Extraordinary
Think they need to review their PR skills (and conscience)
Extraordinary
Think they need to review their PR skills (and conscience)
Reposted by Tom Newsom-Davis
When the conference organizers ask if you can send in your slides a week in advance
April 16, 2025 at 3:08 AM
When the conference organizers ask if you can send in your slides a week in advance
❗️FLAURA2 approved by NICE❗️
Already on BlueTeq!
Now an option for 1L EGFR+ pts
Worth familiarising yourself with the higher risk subgroups that seemed to better with this regimen
Already on BlueTeq!
Now an option for 1L EGFR+ pts
Worth familiarising yourself with the higher risk subgroups that seemed to better with this regimen
NICE has recommended Osimertinib with pemetrexed and platinum-based chemotherapy (based on the FLAURA2 trial) as an option for untreated advanced NSCLC in adults whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
April 10, 2025 at 10:34 AM
❗️FLAURA2 approved by NICE❗️
Already on BlueTeq!
Now an option for 1L EGFR+ pts
Worth familiarising yourself with the higher risk subgroups that seemed to better with this regimen
Already on BlueTeq!
Now an option for 1L EGFR+ pts
Worth familiarising yourself with the higher risk subgroups that seemed to better with this regimen
❗️BTOG / NLCA ‘State of the Nation’ webinar on 15th May❗️
The National Lung Cancer Audit has been instrumental in improvement of lung cancer outcomes in UK
Come and hear about our successes and challenges. Neal Navani always gives a beautifully clear and concise talk. 👍
The National Lung Cancer Audit has been instrumental in improvement of lung cancer outcomes in UK
Come and hear about our successes and challenges. Neal Navani always gives a beautifully clear and concise talk. 👍
April 9, 2025 at 12:32 PM
❗️BTOG / NLCA ‘State of the Nation’ webinar on 15th May❗️
The National Lung Cancer Audit has been instrumental in improvement of lung cancer outcomes in UK
Come and hear about our successes and challenges. Neal Navani always gives a beautifully clear and concise talk. 👍
The National Lung Cancer Audit has been instrumental in improvement of lung cancer outcomes in UK
Come and hear about our successes and challenges. Neal Navani always gives a beautifully clear and concise talk. 👍
This is an excellent series of discussions. Informed and informative. Highly recommend it.
@katherinesleeman.bsky.social especially good, as she is always.
@katherinesleeman.bsky.social especially good, as she is always.
Today's episode of Inside Health (BBC R4) asks how could we be certain someone wants to die, who brings up the conversation & safeguarding.
I was part of the panel discussion with @profmarktaubert.bsky.social @katherinesleeman.bsky.social & @drdavidnicholl.bsky.social
www.bbc.co.uk/sounds/play/...
I was part of the panel discussion with @profmarktaubert.bsky.social @katherinesleeman.bsky.social & @drdavidnicholl.bsky.social
www.bbc.co.uk/sounds/play/...
Inside Health - Assisted dying: How could we be certain someone wants to die? - BBC Sounds
James Gallagher and the panel discuss the safeguarding implications of the proposed bill.
www.bbc.co.uk
April 6, 2025 at 8:57 PM
This is an excellent series of discussions. Informed and informative. Highly recommend it.
@katherinesleeman.bsky.social especially good, as she is always.
@katherinesleeman.bsky.social especially good, as she is always.
Reposted by Tom Newsom-Davis
Very important dataset and a set forward to potential ambulatory delivery in the future.
Happy to share our recent #ESMOOpen paper on the #safety and #feasibility of #outpatient administration of #tarlatamab as part of the #DeLLphi300 study providing evidence that support less intensive monitoring at initiation of therapy. #LCSM 🫁 #SCLC 😀
doi.org/10.1016/j.es...
doi.org/10.1016/j.es...
April 5, 2025 at 11:06 AM
Very important dataset and a set forward to potential ambulatory delivery in the future.
🧐 Are you a 🇬🇧 Healthcare Professional treating lung cancer?
🤔 Do you want to learn how clinical research runs, whilst advancing your career?
💥 Be an Associate PI of a trial!
🥳 eVOLVE-Lung02 (I am 🇬🇧 CI) accepted into NIHR Associate PI programme
Details here 👇
www.nihr.ac.uk/career-devel...
🤔 Do you want to learn how clinical research runs, whilst advancing your career?
💥 Be an Associate PI of a trial!
🥳 eVOLVE-Lung02 (I am 🇬🇧 CI) accepted into NIHR Associate PI programme
Details here 👇
www.nihr.ac.uk/career-devel...
www.nihr.ac.uk
April 4, 2025 at 8:19 AM
🧐 Are you a 🇬🇧 Healthcare Professional treating lung cancer?
🤔 Do you want to learn how clinical research runs, whilst advancing your career?
💥 Be an Associate PI of a trial!
🥳 eVOLVE-Lung02 (I am 🇬🇧 CI) accepted into NIHR Associate PI programme
Details here 👇
www.nihr.ac.uk/career-devel...
🤔 Do you want to learn how clinical research runs, whilst advancing your career?
💥 Be an Associate PI of a trial!
🥳 eVOLVE-Lung02 (I am 🇬🇧 CI) accepted into NIHR Associate PI programme
Details here 👇
www.nihr.ac.uk/career-devel...
Reposted by Tom Newsom-Davis
What!? Tiramisu is younger than my dad? Also the 1940s saw great additions to our cuisine. Weird how young ciabatta is! Fun chart shows several foods that were invented surprisingly recently. Source: buff.ly/nvQgUns
March 30, 2025 at 12:05 PM
What!? Tiramisu is younger than my dad? Also the 1940s saw great additions to our cuisine. Weird how young ciabatta is! Fun chart shows several foods that were invented surprisingly recently. Source: buff.ly/nvQgUns
Wow
Extraordinary times
Extraordinary times
Peter Marks leaving FDA. “However it has become clear that truth and transparency are not desired by the Secretary, but rather he wishes subservient confirmation of his misinformation and lies.” From Bloomberg. apple.news/AIvBYR8IDQru...
March 29, 2025 at 5:54 PM
Wow
Extraordinary times
Extraordinary times
Reposted by Tom Newsom-Davis
New data from the LAURA trial shared at #ELCC25 today shows promising results for Stage 3 unresectable EGFR+ #lungcancer.
Giving osimertinib after chemoradiation meant people went much longer before needing further treatment — over 40 months, compared to just 9 months without it. #LCSM
Giving osimertinib after chemoradiation meant people went much longer before needing further treatment — over 40 months, compared to just 9 months without it. #LCSM
March 28, 2025 at 5:38 PM
New data from the LAURA trial shared at #ELCC25 today shows promising results for Stage 3 unresectable EGFR+ #lungcancer.
Giving osimertinib after chemoradiation meant people went much longer before needing further treatment — over 40 months, compared to just 9 months without it. #LCSM
Giving osimertinib after chemoradiation meant people went much longer before needing further treatment — over 40 months, compared to just 9 months without it. #LCSM
Predicting surgical complexity following neo-adjuvant chemoIO
Single centre 🇬🇧 study
👉 43% defined as complex
🔺 Risk score includes x3 variables:
❇️ CN2
❇️ Absence of nodal response
❇️ PD-L1 >50%
#ELCC25
Single centre 🇬🇧 study
👉 43% defined as complex
🔺 Risk score includes x3 variables:
❇️ CN2
❇️ Absence of nodal response
❇️ PD-L1 >50%
#ELCC25
March 28, 2025 at 2:37 PM
Predicting surgical complexity following neo-adjuvant chemoIO
Single centre 🇬🇧 study
👉 43% defined as complex
🔺 Risk score includes x3 variables:
❇️ CN2
❇️ Absence of nodal response
❇️ PD-L1 >50%
#ELCC25
Single centre 🇬🇧 study
👉 43% defined as complex
🔺 Risk score includes x3 variables:
❇️ CN2
❇️ Absence of nodal response
❇️ PD-L1 >50%
#ELCC25
LAURA OS update (LBA4)
👉 Now 31% maturity
❇️ 78% in PBO grp got Osi at PD
❇️ Improved PFS2
❇️ Trend ⬆️ OS HR 0.67, not significant
💭 Confirm activity of Osi
💭 Crossover impacts OS difference
💭 Final maturity due @ 60%
💭 Surprised 1/3 Osi pts = no further treatment at PD
#ELCC25
👉 Now 31% maturity
❇️ 78% in PBO grp got Osi at PD
❇️ Improved PFS2
❇️ Trend ⬆️ OS HR 0.67, not significant
💭 Confirm activity of Osi
💭 Crossover impacts OS difference
💭 Final maturity due @ 60%
💭 Surprised 1/3 Osi pts = no further treatment at PD
#ELCC25
March 28, 2025 at 2:10 PM
LAURA OS update (LBA4)
👉 Now 31% maturity
❇️ 78% in PBO grp got Osi at PD
❇️ Improved PFS2
❇️ Trend ⬆️ OS HR 0.67, not significant
💭 Confirm activity of Osi
💭 Crossover impacts OS difference
💭 Final maturity due @ 60%
💭 Surprised 1/3 Osi pts = no further treatment at PD
#ELCC25
👉 Now 31% maturity
❇️ 78% in PBO grp got Osi at PD
❇️ Improved PFS2
❇️ Trend ⬆️ OS HR 0.67, not significant
💭 Confirm activity of Osi
💭 Crossover impacts OS difference
💭 Final maturity due @ 60%
💭 Surprised 1/3 Osi pts = no further treatment at PD
#ELCC25
Reposted by Tom Newsom-Davis
2) daraxonrasib (rmc-6236) offering early phase and v impressive activity in g12d g12v 2nd line nsclc. RR 38% and mPFS >10m. V tolerable toxicity profile again. Next will be IO combos, congrats+++ to Revolution Medicines and the investigators. #ELCC25
March 27, 2025 at 4:08 PM
2) daraxonrasib (rmc-6236) offering early phase and v impressive activity in g12d g12v 2nd line nsclc. RR 38% and mPFS >10m. V tolerable toxicity profile again. Next will be IO combos, congrats+++ to Revolution Medicines and the investigators. #ELCC25
Reposted by Tom Newsom-Davis
1) KRYSTAL-7 update on pembro+adagrasib in 1st line pdl1 >50% nsclc. Tox to navigate but mPFS >27m! Further reinforcing the view that ras orchestrates TME, not just cancer cell intrinsic pathways. Massive congrats to investigators, mirati, bms #ELCC25
March 27, 2025 at 4:03 PM
1) KRYSTAL-7 update on pembro+adagrasib in 1st line pdl1 >50% nsclc. Tox to navigate but mPFS >27m! Further reinforcing the view that ras orchestrates TME, not just cancer cell intrinsic pathways. Massive congrats to investigators, mirati, bms #ELCC25
Great ROS1 TKI summary slide from Julian Mazieres
March 27, 2025 at 4:07 PM
Great ROS1 TKI summary slide from Julian Mazieres
COCOON: mitigating cutaneous toxicity of Amivantamab
✅ 60% reduction in Gr2+ dermatology AE
✅ Reduction scalp issues+ paronychia
✅ Fewer Ami dose amendments needed
💭 This regimen should be instigated immediately for any patient starting Amivantamab based therapy
#ELCC25
✅ 60% reduction in Gr2+ dermatology AE
✅ Reduction scalp issues+ paronychia
✅ Fewer Ami dose amendments needed
💭 This regimen should be instigated immediately for any patient starting Amivantamab based therapy
#ELCC25
March 27, 2025 at 4:05 PM
COCOON: mitigating cutaneous toxicity of Amivantamab
✅ 60% reduction in Gr2+ dermatology AE
✅ Reduction scalp issues+ paronychia
✅ Fewer Ami dose amendments needed
💭 This regimen should be instigated immediately for any patient starting Amivantamab based therapy
#ELCC25
✅ 60% reduction in Gr2+ dermatology AE
✅ Reduction scalp issues+ paronychia
✅ Fewer Ami dose amendments needed
💭 This regimen should be instigated immediately for any patient starting Amivantamab based therapy
#ELCC25
Case controlled indirect comparison of Taletrectinib v Crizotinib in ROS1 NSCLC
👉 From TRUST I + II / PROFILE 1091 trials
✅ ORR 90% v 71%
✅ Improved PFS, HR 0.48
👉 Similar Gr3 TRAEs
💭 Ph3 head-2-head ongoing
💭 In meanwhile, this suggests Taletrectinib superior
💭 Would like to see CNS data
#ELCC25
👉 From TRUST I + II / PROFILE 1091 trials
✅ ORR 90% v 71%
✅ Improved PFS, HR 0.48
👉 Similar Gr3 TRAEs
💭 Ph3 head-2-head ongoing
💭 In meanwhile, this suggests Taletrectinib superior
💭 Would like to see CNS data
#ELCC25
March 27, 2025 at 3:55 PM
Case controlled indirect comparison of Taletrectinib v Crizotinib in ROS1 NSCLC
👉 From TRUST I + II / PROFILE 1091 trials
✅ ORR 90% v 71%
✅ Improved PFS, HR 0.48
👉 Similar Gr3 TRAEs
💭 Ph3 head-2-head ongoing
💭 In meanwhile, this suggests Taletrectinib superior
💭 Would like to see CNS data
#ELCC25
👉 From TRUST I + II / PROFILE 1091 trials
✅ ORR 90% v 71%
✅ Improved PFS, HR 0.48
👉 Similar Gr3 TRAEs
💭 Ph3 head-2-head ongoing
💭 In meanwhile, this suggests Taletrectinib superior
💭 Would like to see CNS data
#ELCC25
Tobemstomig (LAG3/PD1 bispecific) + chemo in 1L NSCLC
👉 Randomised Ph2
❌ No ORR benefit
❌ No PFS benefit
❌ Higher Gr3+ TRAEs
💭 Not active combination
💭 Reality check on growing bispecific excitement
💭 Disappointing. LAG3 is hard to target.
#ELCC25
👉 Randomised Ph2
❌ No ORR benefit
❌ No PFS benefit
❌ Higher Gr3+ TRAEs
💭 Not active combination
💭 Reality check on growing bispecific excitement
💭 Disappointing. LAG3 is hard to target.
#ELCC25
March 27, 2025 at 3:47 PM
Tobemstomig (LAG3/PD1 bispecific) + chemo in 1L NSCLC
👉 Randomised Ph2
❌ No ORR benefit
❌ No PFS benefit
❌ Higher Gr3+ TRAEs
💭 Not active combination
💭 Reality check on growing bispecific excitement
💭 Disappointing. LAG3 is hard to target.
#ELCC25
👉 Randomised Ph2
❌ No ORR benefit
❌ No PFS benefit
❌ Higher Gr3+ TRAEs
💭 Not active combination
💭 Reality check on growing bispecific excitement
💭 Disappointing. LAG3 is hard to target.
#ELCC25
Pan-KRASi: RMC-6236
👉 NSCLC pts from Ph1 study
❇️ 200mg = Ph3 dose
❗️TRAE: mucocutaneous, GI, liver
❗️ Rash prophylaxis needed
👉 Clinical data from G12X popn:
❇️ ORR 38%
❇️ mPFS = 9.8m
Ph3 RASolve-301 underway
💭 Need breakdown by mutant type
💭 Press release: safe combo w Pembro
#ELCC25
👉 NSCLC pts from Ph1 study
❇️ 200mg = Ph3 dose
❗️TRAE: mucocutaneous, GI, liver
❗️ Rash prophylaxis needed
👉 Clinical data from G12X popn:
❇️ ORR 38%
❇️ mPFS = 9.8m
Ph3 RASolve-301 underway
💭 Need breakdown by mutant type
💭 Press release: safe combo w Pembro
#ELCC25
March 27, 2025 at 3:28 PM
Pan-KRASi: RMC-6236
👉 NSCLC pts from Ph1 study
❇️ 200mg = Ph3 dose
❗️TRAE: mucocutaneous, GI, liver
❗️ Rash prophylaxis needed
👉 Clinical data from G12X popn:
❇️ ORR 38%
❇️ mPFS = 9.8m
Ph3 RASolve-301 underway
💭 Need breakdown by mutant type
💭 Press release: safe combo w Pembro
#ELCC25
👉 NSCLC pts from Ph1 study
❇️ 200mg = Ph3 dose
❗️TRAE: mucocutaneous, GI, liver
❗️ Rash prophylaxis needed
👉 Clinical data from G12X popn:
❇️ ORR 38%
❇️ mPFS = 9.8m
Ph3 RASolve-301 underway
💭 Need breakdown by mutant type
💭 Press release: safe combo w Pembro
#ELCC25
🇬🇧 healthcare has many challenges & shortcomings
But we lead the world in lung cancer screening (many of these pioneers being on this paper)
Now in routine clinical practice, causing stage shift. I see the effects every week.
We need to bang the drum more about this 🥁
But we lead the world in lung cancer screening (many of these pioneers being on this paper)
Now in routine clinical practice, causing stage shift. I see the effects every week.
We need to bang the drum more about this 🥁
Paper on lung cancer screening from London.
-Invitations sent to people 55–77yo listed as smokers at their PCP. 31% responded.
-At baseline CT scan, 2% had lung cancer diagnosed!!!
(1.3% on first scan, others at 3 and 6 month f/u). This is in line with prior data.
www.thelancet.com/journals/lan...
-Invitations sent to people 55–77yo listed as smokers at their PCP. 31% responded.
-At baseline CT scan, 2% had lung cancer diagnosed!!!
(1.3% on first scan, others at 3 and 6 month f/u). This is in line with prior data.
www.thelancet.com/journals/lan...
Low-dose CT for lung cancer screening in a high-risk population (SUMMIT): a prospective, longitudinal cohort study
Large-scale lung cancer screening is effective and can be delivered efficiently to
an ethnically and socioeconomically diverse population.
www.thelancet.com
March 26, 2025 at 7:01 PM
🇬🇧 healthcare has many challenges & shortcomings
But we lead the world in lung cancer screening (many of these pioneers being on this paper)
Now in routine clinical practice, causing stage shift. I see the effects every week.
We need to bang the drum more about this 🥁
But we lead the world in lung cancer screening (many of these pioneers being on this paper)
Now in routine clinical practice, causing stage shift. I see the effects every week.
We need to bang the drum more about this 🥁